N-[5-[3-(5-fluoro-3-pyridinyl)-1H-indazol-6-yl]-4-methyl-1,3-thiazol-2-yl]-2-(4-methylpiperazin-1-yl)acetamide
C23H24FN7OS — CID 156760471
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[5-[3-(5-fluoro-3-pyridinyl)-1H-indazol-6-yl]-4-methyl-1,3-thiazol-2-yl]-2-(4-methylpiperazin-1-yl)acetamide
N-[5-[3-(5-fluoro-3-pyridinyl)-1H-indazol-6-yl]-4-methyl-1,3-thiazol-2-yl]-2-(4-methylpiperazin-1-yl)acetamide (PubChem CID 156760471) has the molecular formula C23H24FN7OS and a molecular weight of 465.56 g/mol. Its IUPAC name is N-[5-[3-(5-fluoro-3-pyridinyl)-1H-indazol-6-yl]-4-methyl-1,3-thiazol-2-yl]-2-(4-methylpiperazin-1-yl)acetamide.
Molecular Properties
| Compound Name | N-[5-[3-(5-fluoro-3-pyridinyl)-1H-indazol-6-yl]-4-methyl-1,3-thiazol-2-yl]-2-(4-methylpiperazin-1-yl)acetamide |
|---|---|
| PubChem CID | 156760471 |
| Molecular Formula | C23H24FN7OS |
| Molecular Weight | 465.56 g/mol |
| Exact Mass | 465.17 |
| IUPAC Name | N-[5-[3-(5-fluoro-3-pyridinyl)-1H-indazol-6-yl]-4-methyl-1,3-thiazol-2-yl]-2-(4-methylpiperazin-1-yl)acetamide |
| SMILES | Cc1nc(NC(=O)CN2CCN(C)CC2)sc1-c1ccc2c(-c3cncc(F)c3)n[nH]c2c1 |
| InChI | InChI=1S/C23H24FN7OS/c1-14-22(33-23(26-14)27-20(32)13-31-7-5-30(2)6-8-31)15-3-4-18-19(10-15)28-29-21(18)16-9-17(24)12-25-11-16/h3-4,9-12H,5-8,13H2,1-2H3,(H,28,29)(H,26,27,32) |
| InChIKey | ZPSMCPKVGOVPEN-UHFFFAOYSA-N |
| XLogP | 3.38 |
| TPSA | 90.04 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 465.56 |
| LogP ≤ 5 | 3.38 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 156760471 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.